Dr. Stephan A Grupp M.D.
Hematologist (Pediatric) | Pediatric Hematology-Oncology34th & Civic Center Blvd Children's Hospital Philadelphia PA, 19104
As an attending physician in the Cancer Center, the director of Translational Research of the Center for Childhood Cancer Research, and the director of the Stem Cell Laboratory, I take on many roles h ...
Education and Training
Univ of Cincinnati Coll of Med, Cincinnati Oh 1987
University of Cincinnati College of Medicine 1987
DermatologyAmerican Board of DermatologyABD
- Inhibition of tumor growth in a human neuroblastoma xenograft model with TNP-470.
- CD34 selection as a stem cell purging strategy for neuroblastoma: preclinical and clinical studies.
- Rapid-sequence tandem transplant for children with high-risk neuroblastoma.
- The angiogenesis inhibitor tnp-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease.
- Angiogenesis inhibitor TNP-470 during bone marrow transplant: safety in a preclinical model.
- Cytoplasmic micro heavy chain confers sensitivity to dexamethasone-induced apoptosis in early B-lineage acute lymphoblastic leukemia.
- Role of the BCR complex in B cell development, activation, and leukemic transformation.
- Rapamycin is active against B-precursor leukemia in vitro and in vivo, an effect that is modulated by IL-7-mediated signaling.
- An unexpectedly high incidence of Epstein-Barr virus lymphoproliferative disease after CD34+ selected autologous peripheral blood stem cell transplant in neuroblastoma.
- Unmasking Evans syndrome: T-cell phenotype and apoptotic response reveal autoimmune lymphoproliferative syndrome (ALPS).
- Safety and efficacy of allogeneic PBSC collection in normal pediatric donors: the pediatric blood and marrow transplant consortium experience (PBMTC) 1996-2003.
- The mTOR inhibitor CCI-779 induces apoptosis and inhibits growth in preclinical models of primary adult human ALL.
- Collection, storage, and infusion of stem cells in children with high-risk neuroblastoma: saving for a rainy day.
- Rapamycin improves lymphoproliferative disease in murine autoimmune lymphoproliferative syndrome (ALPS).
- High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update.
- In vivo control of acute lymphoblastic leukemia by immunostimulatory CpG oligonucleotides.
- A prospective study of G-CSF primed bone marrow as a stem-cell source for allogeneic bone marrow transplantation in children: a Pediatric Blood and Marrow Transplant Consortium (PBMTC) study.
- Targeting Notch signaling in autoimmune and lymphoproliferative disease.
- Thymic stromal-derived lymphopoietin induces proliferation of pre-B leukemia and antagonizes mTOR inhibitors, suggesting a role for interleukin-7Ralpha signaling.
- Stem cell transplantation for neuroblastoma.
- mTOR inhibitors are synergistic with methotrexate: an effective combination to treat acute lymphoblastic leukemia.
- Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease.
- Treatment with sirolimus results in complete responses in patients with autoimmune lymphoproliferative syndrome.
- Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies.
- Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo.
- Reduced-intensity allogeneic transplantation in pediatric patients ineligible for myeloablative therapy: results of the Pediatric Blood and Marrow Transplant Consortium Study ONC0313.
- Long-term protection from syngeneic acute lymphoblastic leukemia by CpG ODN-mediated stimulation of innate and adaptive immune responses.
- A phase I/II study of the safety and efficacy of the addition of sirolimus to
- Advances in the management and understanding of autoimmune lymphoproliferative syndrome (ALPS).
- Natural killer cell consolidation for acute myelogenous leukemia: a cell therapy ready for prime time?
- Anti-CD13 Abs in children with extensive chronic GVHD and their relation to soluble CD13 after allogeneic blood and marrow transplantation from a Children's Oncology Groups Study, ASCT0031.
- Autologous and allogeneic cellular therapies for high-risk pediatric solid tumors.
- Allogeneic marrow transplantation in children with acute leukemia: careful comparison with chemotherapy alternatives required.
- Adoptive cellular therapy.
- T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.
- Treatment of advanced leukemia in mice with mRNA engineered T cells.
- Noninvasive bioluminescent imaging of primary patient acute lymphoblastic leukemia: a strategy for preclinical modeling.
- The future is now: chimeric antigen receptors as new targeted therapies for childhood cancer.
- Feasibility of a tandem autologous peripheral blood stem cell transplant regimen for high risk neuroblastoma in a cooperative group setting: a Pediatric Oncology Group study: a report from the Children's Oncology Group.
- Sirolimus pharmacokinetics in early postmyeloablative pediatric blood and marrow transplantation.
- A pilot study of tandem high-dose chemotherapy with stem cell rescue as consolidation for high-risk neuroblastoma: Children's Oncology Group study ANBL00P1.
- Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience.
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.
- Regimen-specific effects of RNA-modified chimeric antigen receptor T cells in mice with advanced leukemia.
- Chimeric antigen receptor therapy for cancer.
- Toxicity management for patients receiving novel T-cell engaging therapies.
- Relation of clinical culture method to T-cell memory status and efficacy in xenograft models of adoptive immunotherapy.
- The addition of sirolimus to tacrolimus/methotrexate GVHD prophylaxis in children with ALL: a phase 3 Children's Oncology Group/Pediatric Blood and Marrow Transplant Consortium trial.
- Antibody-modified T cells: CARs take the front seat for hematologic malignancies.
- Preclinical targeting of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells.
- Managing cytokine release syndrome associated with novel T cell-engaging therapies.
- Current concepts in the diagnosis and management of cytokine release syndrome.
- Engineered T cells for cancer therapy.
- Will post-transplantation cell therapies for pediatric patients become standard of care?
- Nature of tumor control by permanently and transiently modified GD2 chimeric antigen receptor T cells in xenograft models of neuroblastoma.
- Chimeric antigen receptor T cells for sustained remissions in leukemia.
- Advances in T-cell therapy for ALL.
- Chimeric antigen receptor T-cell therapy for ALL.
- IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients.
- Risk factors and timing of relapse after allogeneic transplantation in pediatric ALL: for whom and when should interventions be tested?
- Roadblocks to success for RNA CARs in solid tumors.
- CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia.
- Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main Street and Wall Street.
- Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.
- Early memory phenotypes drive T cell proliferation in patients with pediatric malignancies.
- T cells targeting NY-ESO-1 demonstrate efficacy against disseminated neuroblastoma.
- Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy.
- Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia.
- CAR T Cell Therapy in Acute Lymphoblastic Leukemia and Potential for Chronic Lymphocytic Leukemia.
- Toxicities of busulfan/melphalan versus carboplatin/etoposide/melphalan for high-dose chemotherapy with stem cell rescue for high-risk neuroblastoma.
- Improved anti-leukemia activities of adoptively transferred T cells expressing bispecific T-cell engager in mice.
- Cytokine Release Syndrome after Haploidentical Stem Cell Transplantation.
- Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.
- Potent efficacy of combined PI3K/mTOR and JAK or ABL inhibition in murine xenograft models of Ph-like acute lymphoblastic leukemia.
- Repeated loss of target surface antigen after immunotherapy in primary mediastinal large B cell lymphoma.
- Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.
- Refining megatherapy, improving outcome in neuroblastoma.
- IFN-γ directly inhibits murine B-cell precursor leukemia-initiating cell proliferation early in life.
- Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia.
- The ligand-induced membrane IgM association with the cytoskeletal matrix of B cells is not mediated through the Ig alpha beta heterodimer.
- Thrombopoietic activity of recombinant human interleukin 11 (rHuIL-11) in normal and myelosuppressed nonhuman primates.
- Role of mu heavy chain in B cell development. I. Blocked B cell maturation but
- Unrelated And Partially Matched Related Donor PSCT w/ TCR ?? Depletion for Patients With BMF
- Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
- Study Comparing Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients
- CD22 Redirected Autologous T Cells for ALL
- A Multi-Center Study Evaluating KTE-C19 in Pediatric and Adolescent Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
- CD19 CART Long Term Follow Up (LTFU) Study
- Expanded Access Protocol Using CD3+/CD19+ Depleted PBSC
- Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies
- 2012 Philadelphia Super Doctors
- Brain Tumor
- Acute Myeloid Leukemia (aml)
- Dermal Aesthetics
- Extra Corporeal Shockwave Therapy
- Dana-Farber Cancer Inst, Pediatric Hematology-Oncology; Children'S Hosp, Pediatrics
- Children's Hospital Boston
- Children's Hospital Program
Dr. Stephan A Grupp M.D.'s Practice location
Philadelphia, PA 19104Get Direction
Philadelphia, PA 19104Get Direction
Philadelphia, PA 19104Get Direction
Dr. Stephan A Grupp M.D.'s reviewsWrite Review
Patient Experience with Dr. Grupp
- L-Arginine Health Benefits for Fertility
What is L-arginine?L-arginine is an amino acid that can be obtained from the diet, particularly from protein sources, such as red meat, eggs, poultry, fish, and dairy products. L-arginine is also made in laboratories and used as supplements to help support heart health, mental capabilities, and...
- Raising a Child with Autism
Autism spectrum disorder (ASD), or autism, is a term used to describe a group of complex brain disorders in human beings. These disorders affect the social interaction of a person, verbal skills, nonverbal communication, and repetitive behaviors, along with any activity that needs a person to react...
- Potential Causes of Leukopenia
IntroductionA decrease in the number of white blood cells (WBCs) is referred to as leukopenia. There are several causes for leukopenia. It may be due to certain drugs, cancer, radiation and chemotherapy for cancer, stem cell transplant, surgery, steroids, or autoimmune disorders. The immune system...
- Study Finds 3% of Pediatric Non-Hodgkin Lymphoma Cases Are Transplant Recipients
Lymphoma is a blood cancer that affects both children and adults.Lymphoma begins its growth in the lymphatic white blood cells of the lymph system. This system is a major warrior in fighting off infections and diseases. It is part of the body’s immunity team.The lymph system loops throughout the...
- How Is Leukemia Diagnosed?
Leukemia in its early stages may present no signs or symptoms, as these only appear when the leukemia cells have taken over a large number of normal blood cells. A person with leukemia is very lucky indeed if early-stage detection occurs incidentally, through a routine blood test or one done for...
PurpuraPurpura refers to purple-colored spots that are usually seen on the skin, including mucous membranes and other organs. It is also called skin hemorrhages or blood spots.Purpura is usually recognized when there is pooling of blood under the skin due to ruptured small blood vessels. The size of...
- Dr. Michael D Hogarty M.D.34th & Civic Center Blvd Philadelphia PA 19104
- Dr. Naomi Balamuth M.D.34th & Civic Center Blvd Philadelphia PA 19104
- Dr. Nancy J Bunin M.D.34th & Civic Center Blvd Philadelphia PA 19104
- Dr. Edward F Attiyeh M.D.34th & Civic Center Blvd. Philadelphia PA 19104
- Dr. Mortimer Poncz M.D.34th & Civic Center Blvd Philadelphia PA 19104
- Dr. Peter C Adamson M.D.34th & Civic Center Blvd. Philadelphia PA 19104